Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

83.99 +4.36 (+5.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,453,364
Open 81.20
Bid (Size) 63.94 (100)
Ask (Size) 85.00 (800)
Prev. Close 79.63
Today's Range 81.20 - 84.64
52wk Range 19.45 - 103.00
Shares Outstanding 55,307,775
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Streaming Wars Go Hostile Just as Wall Street Braces for the Fed ↗
Stocks slipped from record levels on Monday as investors shifted into “wait-and-see” mode ahead of Wednesday’s Fed decision. At the same time, Hollywood turned into a live-fire M&A battlefield, with... 
Via Chartmill
Topics Economy
News headline image
What's going on in today's session ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill

Performance

YTD
+105.4%
+105.4%
1 Month
+29.6%
+29.6%
3 Month
+71.0%
+71.0%
6 Month
+83.1%
+83.1%
1 Year
+113.6%
+113.6%

More News

Read More
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
What to Expect from Kymera Therapeutics's Earnings ↗
Via Benzinga
News headline image
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Why Is KYMR Stock Up 30% Pre-Market Today? ↗
Via Stocktwits
Topics Economy
News headline image
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Kymera (KYMR) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
10 Analysts Have This To Say About Kymera Therapeutics ↗
Via Benzinga
News headline image
Kymera Therapeutics Inc (NASDAQ:KYMR) Q3 2025 Earnings: Clinical Progress Overshadows Financial Miss ↗
Via Chartmill
News headline image
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts ↗
Via Benzinga
News headline image
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views ↗
Via Benzinga
News headline image
This Chubb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
Via Benzinga
News headline image
Kymera Therapeutics Inc (NASDAQ:KYMR) Reports Q2 2025 Earnings Miss, Stock Dips Pre-Market ↗
Via Chartmill
Topics Earnings
News headline image
Kymera Revenue Drops 55 Percent in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' ↗
Via Benzinga
News headline image
Beyond The Numbers: 8 Analysts Discuss Kymera Therapeutics Stock ↗
Via Benzinga
News headline image
Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Via Benzinga
News headline image
Earnings Scheduled For August 11, 2025 ↗
Via Benzinga
News headline image
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit ↗
Via Stocktwits
News headline image
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies ↗
Via Benzinga
News headline image
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Via MarketBeat
News headline image
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? ↗
Via Benzinga

Frequently Asked Questions

Is Kymera Therapeutics, Inc. - Common Stock publicly traded?
Yes, Kymera Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Kymera Therapeutics, Inc. - Common Stock trade on?
Kymera Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kymera Therapeutics, Inc. - Common Stock?
The ticker symbol for Kymera Therapeutics, Inc. - Common Stock is KYMR on the Nasdaq Stock Market
What is the current price of Kymera Therapeutics, Inc. - Common Stock?
The current price of Kymera Therapeutics, Inc. - Common Stock is 83.99
When was Kymera Therapeutics, Inc. - Common Stock last traded?
The last trade of Kymera Therapeutics, Inc. - Common Stock was at 12/19/25 04:00 PM ET
What is the market capitalization of Kymera Therapeutics, Inc. - Common Stock?
The market capitalization of Kymera Therapeutics, Inc. - Common Stock is 4.65B
How many shares of Kymera Therapeutics, Inc. - Common Stock are outstanding?
Kymera Therapeutics, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.